- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Iloprost fails to Improve organ function in patients with septic shock and severe endotheliopathy: JAMA
A recent clinical trial published in the Journal of American Medical Association revealed that the drug iloprost, commonly used to treat vascular conditions, does not improve organ function in patients with septic shock and severe endotheliopathy. The study was conducted across 6 hospitals in Denmark to explore whether iloprost could help reduce organ dysfunction in patients with elevated levels of soluble thrombomodulin which is a marker of endotheliopathy. However, the results showed no significant difference between the iloprost-treated group and the ones receiving a placebo.
This double-blinded trial ran from November 2019 to July 2022 and included a total of 279 adult ICU patients diagnosed with septic shock and severe endotheliopathy by plasma soluble thrombomodulin levels greater than 10 ng/mL. The patients were randomly assigned to receive either iloprost which was administered via intravenous infusion at a dosage of 1 ng/kg/min for 72 hours, or a placebo. The primary objective was to assess the impact of iloprost on the severity of organ failure which was measured by the Sequential Organ Failure Assessment (SOFA) score is a common scale used to evaluate organ dysfunction in critical care. Secondary outcomes included mortality at 90 days and the occurrence of serious adverse events or reactions.
After the interim analysis, the trial was halted for futility which indicated that the treatment was unlikely to provide any substantial benefit. The mean daily SOFA score in the ICU reflected the severity of organ dysfunction which was 10.6 in the iloprost group and 10.5 in the placebo group. The 90-day mortality rate was also similar between the groups, with 57% of patients in the iloprost group and 51% in the placebo group succumbing to their illness (adjusted relative risk: 1.12, 95% CI: 0.91-1.40, P = 0.33). Also, 18% of patients in the iloprost group faced serious adverse events when compared to 15% in the placebo group by further demonstrating no significant difference. Overall, the findings of this trial suggest that iloprost is unlikely to be beneficial for patients with septic shock and severe endotheliopathy.
Source:
Bestle, M. H., Stensballe, J., Lange, T., Clausen, N. E., Søe-Jensen, P., Pedersen, K. H., Gybel-Brask, M., Kjær, M.-B. N., Steensen, C. O., Jensen, D. B., Gärtner, R., Schønemann-Lund, M., Kristiansen, K. T., Lindhardt, A., Johansson, P. I., & Perner, A. (2024). Iloprost and Organ Dysfunction in Adults With Septic Shock and Endotheliopathy. In JAMA Network Open (Vol. 7, Issue 9, p. e2432444). American Medical Association (AMA). https://doi.org/10.1001/jamanetworkopen.2024.32444
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751